

Vicore to Present at Upcoming Investor Conferences

Stockholm, November 14, 2024 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:

- **Stifel 2024 Healthcare Conference**

Location: New York, United States

Presenter: Ahmed Mousa, CEO

Presentation Date and Time: November 18 at 9:10 AM ET/3:10 PM CET

Webcast: <https://wsw.com/webcast/stifel96/vico/2103734>

- **SEB Healthcare Seminar**

Location: Stockholm, Sweden

Presenter: Hans Jeppsson, CFO

Presentation Date and Time: November 20 at 4:40 AM ET/10:40 AM CET

- **DNB Nordic Healthcare Conference**

Location: Oslo, Norway

Presenter: Hans Jeppsson, CFO

Presentation Date and Time: November 26 at 10:15 AM ET/4:15 PM CET

For further information, please contact:

Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com

Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information was submitted for publication on November 14, 2024, at 8:00 CET.

About Vicore Pharma Holding AB

Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) being investigated in a global Phase 2b trial in IPF. Almee™ is an investigational digital therapeutic in clinical development that is based on cognitive behavioral therapy and created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, which the Company believes reflects its potential to have transformative impact. Using its expertise in ATRAG chemistry and biology, Vicore is further developing its pipeline with several new therapies across additional indications. The company's shares are listed on Nasdaq Stockholm's main market (VICO). www.vicorepharma.com



Press Release
14 November 2024 08:00:00 CET

Attachments

[Vicore to Present at Upcoming Investor Conferences](#)